Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cetuximab + docetaxel + cisplatin as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
2008-004869-25Phase 2Completed
- Sponsor
- GORTEC
- Start
- Nov 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Nov 2008; status: completed.
02
Drugs
cetuximabdocetaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-004869-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004869-25.